Lead Product(s) : Dexlansoprazole
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Devonian’s Subsidiary Launches Generic Dexlansoprazole (Dexilant®) in Canada
Details : Dexilant-Generic (dexlansoprazole) is a proton pump inhibitor for healing erosive esophagitis and treating heartburn associated with non-erosive GERD.
Product Name : Dexilant-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 27, 2024
Lead Product(s) : Dexlansoprazole
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dexlansoprazole
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : SAMI Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 07, 2021
Lead Product(s) : Dexlansoprazole
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : SAMI Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dexlansoprazole
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Compare the Bioavailability (BA) of Dexlansoprazole Delayed-release Capsules
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 11, 2019
Lead Product(s) : Dexlansoprazole
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dexlansoprazole
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 23, 2017
Lead Product(s) : Dexlansoprazole
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dexlansoprazole
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalence Study of Dexlansoprazole Capsules From Two Manufacturing Plants
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 27, 2017
Lead Product(s) : Dexlansoprazole
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dexlansoprazole
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Aosaikang Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 19, 2017
Lead Product(s) : Dexlansoprazole
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Aosaikang Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dexlansoprazole
Therapeutic Area : Gastroenterology
Study Phase : Phase IV
Sponsor : Takeda Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 14, 2017
Lead Product(s) : Dexlansoprazole
Therapeutic Area : Gastroenterology
Highest Development Status : Phase IV
Sponsor : Takeda Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dexlansoprazole
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Aosaikang Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 05, 2017
Lead Product(s) : Dexlansoprazole
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Aosaikang Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dexlansoprazole
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety of Dexlansoprazole on Heartburn Relief in Chinese Patients
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 19, 2016
Lead Product(s) : Dexlansoprazole
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dexlansoprazole
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety of Dexlansoprazole in Healing and Maintaining Healing of Erosive Esophagitis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 19, 2016
Lead Product(s) : Dexlansoprazole
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
